Zevra Cashes in on First FDA-Approved NPC Treatment with PRV

Zevra Cashes in on First FDA-Approved NPC Treatment with PRV

Neil F. McFarlane, Zevra Therapeutics President and CEO After gaining FDA approval for Miplyffa® (arimoclomol) as the first-ever therapy indicated to treat Niemann-Pick disease type C (NPC), Zevra Therapeutics has cashed in on the regulatory win by closing on the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) that came along with the authorization. Because Miplyffa had previously been designated a rare pediatric disease drug, it …